Metronomic chemotherapy with gemcitabine, mitomycin C, and thalidomide for advanced solid tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of three drugs—gemcitabine, mitomycin C, and thalidomide—given in a low, frequent 'metronomic' schedule to treat advanced solid tumors that have already been treated. The goal is to see if this approach can slow or stop tumor growth with fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a solid tumor that has spread or cannot be removed, and you have already had some treatment.
- You are able to take care of yourself and are up and about at least half the day (ECOG 0 or 1).
- Your liver and kidneys are working well enough (checked by blood tests).
- Your blood counts are in a safe range (checked by blood tests).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing two new drugs (DB-1311 with BNT327 or DB-1305) in people with certain advanced or metastatic solid tumors that have not responded to prior treatments. It aims to see if the combination shrinks tumors or slows cancer growth.
This study tests how well and how safely different combinations of cancer drugs work for people with metastatic or inoperable locally advanced breast cancer. It may help by finding a better treatment option and collecting information to guide future care.
This trial tests a combination of immunotherapy (camrelizumab) plus chemotherapy, with or without thalidomide, as a first treatment for advanced non-small cell lung cancer. It aims to see if adding thalidomide improves outcomes.
This trial tests whether adding thalidomide to standard chemotherapy can help reduce nausea and vomiting in people with advanced pancreatic cancer. It is for patients who have not yet received any cancer treatment.
This trial tests a new drug (GRWD5769) that may help your immune system fight cancer. It is for people with advanced solid tumors that have stopped responding to standard treatments, including certain types of cervical, liver, and other cancers.
This Phase 1 trial tests a new medicine (HG381) in people with advanced solid tumors to see how safe it is and how it works in the body. It may help if standard treatments have already stopped working or aren’t possible for you.
Hear when a new Solid Tumor Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.